scFv(CEA)-CD28-CD3zeta CAR-T Lentivirus

The scFv(CEA)-CD28-CD3zeta CAR-T lentivirus is a second-generation replication-deficient lentiviral vector designed to deliver a chimeric antigen receptor that combines precise CEA recognition with robust and controllable T cell activation. This vector incorporates a high-affinity anti-CEA single-chain variable fragment for selective target binding, paired with a rationally designed hinge/transmembrane region and an intracellular CD28 co-stimulatory domain fused to the CD3zeta signaling module. This structure supports durable surface expression and robust downstream signaling upon antigen binding, promoting rapid T cell activation, proliferation, and cytokine production while maintaining functional persistence. The vector utilizes a self-inactivating backbone and a separate packaging system to enhance biosafety and reduce the risk of insertional activation, and is designed for stable genomic integration, thus maintaining transgene expression during cell expansion.

This lentiviral vector is ideally suited for preclinical studies focused on CEA-positive solid tumors, including colorectal cancer, gastric cancer, pancreatic cancer, and certain lung adenocarcinomas. It enables the rapid generation of CEA-targeted CAR-T cells for in vitro evaluation of cytotoxicity, cytokine release, degranulation, activation kinetics, and exhaustion markers, as well as for co-culture studies investigating tumor-immune interactions. In vivo, it supports proof-of-concept efficacy studies in xenograft or patient-derived models, facilitating the assessment of tumor control, CAR-T cell persistence, and biodistribution. The vector is also valuable in safety risk assessment processes, including on-target/off-target tumor assessment and sensitivity assessment to varying antigen densities, thus informing target selection and clinical translation strategies.